An unfolded protein response is the initial cellular response to the expression of mutant matrilin-3 in a mouse model of multiple epiphyseal dysplasia
- First Online:
- Cite this article as:
- Nundlall, S., Rajpar, M.H., Bell, P.A. et al. Cell Stress and Chaperones (2010) 15: 835. doi:10.1007/s12192-010-0193-y
Multiple epiphyseal dysplasia (MED) can result from mutations in matrilin-3, a structural protein of the cartilage extracellular matrix. We have previously shown that in a mouse model of MED the tibia growth plates were normal at birth but developed a progressive dysplasia characterised by the intracellular retention of mutant matrilin-3 and abnormal chondrocyte morphology. By 3 weeks of age, mutant mice displayed a significant decrease in chondrocyte proliferation and dysregulated apoptosis. The aim of this current study was to identify the initial post-natal stages of the disease. We confirmed that the disease phenotype is seen in rib and xiphoid cartilage and, like tibia growth plate cartilage is characterised by the intracellular retention of mutant matrilin-3. Gene expression profiling showed a significant activation of classical unfolded protein response (UPR) genes in mutant chondrocytes at 5 days of age, which was still maintained by 21 days of age. Interestingly, we also noted the upregulation of arginine-rich, mutated in early stage of tumours (ARMET) and cysteine-rich with EGF-like domain protein 2 (CRELD2) are two genes that have only recently been implicated in the UPR. This endoplasmic reticulum (ER) stress and UPR did not lead to increased chondrocyte apoptosis in mutant cartilage by 5 days of age. In an attempt to alleviate ER stress, mutant mice were fed with a chemical chaperone, 4-sodium phenylbutyrate (SPB). SPB at the dosage used had no effect on chaperone expression at 5 days of age but modestly decreased levels of chaperone proteins at 3 weeks. However, this did not lead to increased secretion of mutant matrilin-3 and in the long term did not improve the disease phenotype. We performed similar studies with a mouse model of Schmid metaphyseal chondrodysplasia, but again this treatment did not improve the phenotype.
KeywordsMatrilin-3ChondrodysplasiaMouse modelUnfolded protein responseChemical chaperonesARMETCRELD2
The rough endoplasmic reticulum (rER) has stringent quality control mechanisms to ensure that only properly folded proteins are allowed to leave the rER, thus mediating the secretion of high-quality functional proteins (Kaufman 1999, 2002; Rutkowski and Kaufman 2004). Correctly folded proteins are translocated to the Golgi apparatus where they undergo additional processing before trafficking to their intended destinations, either secretion into the extracellular matrix (ECM) or embedding in the plasma membrane or to the lysosome.
A number of protein folding disorders result from the accumulation of unfolded or misfolded proteins within the rER, causing ER stress (Kaufman 2002). This ER stress can lead to an upregulation of many rER resident proteins involved in protein folding to protect the cells from the ER stress and is known as an unfolded protein response (UPR).
The chondrodysplasias are a clinically and genetically heterogeneous group of over 200 unique phenotypes that effect the development of the osseous skeleton (Hall 2002). Numerous chondrodysplasias can result from mutations in the genes encoding cartilage extracellular matrix proteins (Superti-Furga et al. 2001) that can sometimes lead to misfolding and an accumulation of mutant protein within the rER (Bateman et al. 2009; Boot-Handford and Briggs 2009). Mutant protein accumulation in the rER is a key pathological feature in a range of different mouse models of chondrodysplasias, primary amongst which are models of pseudoachondroplasia, multiple epiphyseal dysplasia (Leighton et al. 2007; Schmitz et al. 2008) and metaphyseal chondrodysplasia type Schmid (MCDS; Ho et al. 2007; Rajpar et al. 2009; Tsang et al. 2007).
Multiple epiphyseal dysplasia (MED) is a clinically variable and genetically heterogeneous chondrodysplasia that is characterised by mild short stature, joint pain and stiffness and early onset osteoarthritis. Autosomal-dominant forms of MED can result from mutations in the genes encoding three cartilage structural proteins, cartilage oligomeric matrix protein, type IX collagen and matrilin-3 (Briggs and Chapman 2002). Matrilin-3 is the third member of a family of four ECM proteins; matrilin-1 and matrilin-3 are primarily expressed in cartilage, whilst matrilin-2 and matrilin-4 have a wider pattern of expression in a variety of ECM including non-skeletal tissues (Wagener et al. 2005).
Matrilin-3 consists of a single von Willebrand factor A-like domain (A-domain), four epidermal growth factor (EGF)-like motifs and a coiled-coil oligomerization domain (Wagener et al. 1997). All of the MED-causing mutations in MATN3 are found in the single A-domain of matrilin-3 in either the β-strand or α-helix regions (Fresquet et al. 2008; Jackson et al. 2004). The majority of these mutations have been shown to result in the retention of mutant protein in vitro, whereas a smaller proportion of mutations appear to allow the secretion of mutant protein (Cotterill et al. 2005; Fresquet et al. 2008).
In order to determine the precise disease mechanisms that underpin the pathophysiology of MED in vivo, we generated a murine model by introducing a disease-causing Matn3 mutation (p.V194D). This mouse model exhibited significant short-limb dwarfism with a marked reduction in chondrocyte proliferation and dysregulated apoptosis within the cartilage growth plates of the developing limbs. Mutant matrilin-3 was retained within the rER of chondrocytes, and preliminary experiments demonstrated the upregulation of BiP and Grp94 in chondrocytes from 4-day-old mice (Leighton et al. 2007).
The aim of this current study was to use microarray, quantitative real-time reverse-transcriptase polymerase chain reaction (qRT-PCR) and Western blotting to comprehensively characterise the initial cellular response in the post-natal stage of the disease.
2 Materials and methods
2.1 Real-time PCR and Western blot analysis
For qRT-PCR, the rib cages from 5-day-old mice (wild type (wt) and mutant (m/m)) were dissected and treated with collagenase (type 1A, 2 mg/ml) for 1 h at 37°C in Dulbecco’s modified Eagle’s medium (DMEM). The costal cartilage was dissected from individual ribs, and the perichondrium layer was removed. The cartilage was digested a second time with collagenase for 3 h to remove the collagen matrix and release the chondrocytes. The chondrocytes were passed through a cell strainer (70 μm) and washed with DMEM containing 10% FBS and following centrifugation washed again with PBS. The cell pellet was resuspended in 500 μl TriZol (Invitrogen), and total RNA was isolated according to the manufacturer’s instructions. First-strand cDNA was synthesised using random hexamer primers (Superscript III, Invitrogen), and qPCR was performed using the SYBR® green PCR protocol. Primer sequences were: BiP: 5′-ggcaccttcgatgtgtctcttc-3′ and rev: 5′-tccatgacccgctgatcaa-3′; Grp94: 5′-taagctgtatgtacgccgcgt-3′ and rev: 5′-ggagatcatcggaatccacaac-3′; Calnexin: 5′-tga ttt cct ctc cct ccc ctt-3′ and rev: 5′-cac tgg aac ctg ttg atg gtg a-3′; Calreticulin: 5′-gct acg tga agc tgt ttc cga-3′ and rev: 5′-aca tga acc ttc ttg gtg cca g-3’; Erp72: 5′-agt atg agc cca ggt tcc acg t-3′ and rev: 5′-aga agt ctt acg atg gcc cac c-3′. Each experiment included ‘no template’ controls, was run in duplicate and had an 18S RNA control. Each independent experiment was repeated three times, and the results were analysed by independent-samples t test.
For Western blot analysis, chondrocytes were isolated as above, but aliquots of 2 × 105 chondrocytes were prepared and resuspended in 5× sodium dodecyl sulphate (SDS) loading buffer containing DTT. These protein aliquots were separated by 4–12% SDS-polyacrylamide gel electrophoresis (PAGE; Invitrogen) then transferred to nitrocellulose membranes for Western blot analysis. Ponceau staining was used to confirm equal loading of total protein isolates.
Antibodies to key chaperones associated with the unfolded protein response were used at a dilution of either 1:500 (BiP, Grp94, Erp72 and PDI; all from Santa Cruz) or 1:100 (ATF-6 from Imgenex and Bcl-2 from Abcam).
2.2 Histology and immunohistochemistry
Tissue samples were fixed overnight in ice-cold 10% formalin (haematoxylin and eosin (H&E) staining and Terminal deoxynucleotidyl transferase dUTP nick-end labelling (TUNEL)) or 95% ethanol and 5% acetic acid (immunohistochemistry (IHC) and bromodeoxyuridine (BrdU)). Samples were then decalcified in 20% EDTA and embedded in paraffin wax as described previously (Leighton et al. 2007). Antibodies used were rabbit anti-matrilin-3 (R&D), rat anti-BrdU (Abcam) and goat anti-Grp94 (Santa Cruz). Briefly, endogenous peroxidase activity was quenched by a H2O2/methanol wash, followed by hyaluronidase treatment. Samples were blocked with goat serum (for anti-matrilin-3 and anti-BrdU) or rabbit serum (for anti-Grp94) and bovine serum albumin (BSA) in phosphate-buffered saline (PBS) for 1 h and incubated for 1 h with the primary antibody (in PBS/BSA). They were then incubated for 1 h with the relevant secondary antibodies such as biotinylated goat anti-rabbit IgG (Dako Cytomation), biotinylated goat anti-rat (Abcam) or rabbit anti-goat (Santa Cruz) in PBS/BSA with goat/rabbit serum. Slides were then incubated with the ABC complex/HRP reagent for 30 min and developed using DAB. Samples were counterstained with methyl green and mounted with VectaMount. BrdU IHC was performed as above, except the hyaluronidase step was replaced with an antigen retrieval step (i.e. incubated in 4 M HCl for 15 min and then neutralised with 0.1 M borate buffer).
Analysis of apoptosis was performed using the DeadEnd™ fluorometric TUNEL system (Promega) and visualised with a Zeiss Axiovision microscope. Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) while apoptotic cells were stained with fluorescein isothiocyanate (FITC). Nested analysis of variance (ANOVA) was used to assess statistical significance between treated and untreated samples. A value of p < 0.05 was considered statistically significant.
2.3 BrdU labelling of proliferating cells
Twenty-one-day-old mice were injected peritoneally with 0.1 ml of cell proliferation labelling reagent (Amersham) per 10 g of weight and sacrificed after 2 h. The dissected tibias were fixed and analysed by IHC using an anti-BrdU antibody (1:100; Abcam). The number of BrdU-labelled cells was expressed as a proportion of the total population of cells in the proliferative zone. Nested ANOVA was used to assess statistical significance between treated and untreated samples. A value of p < 0.05 was considered statistically significant.
2.4 Ultrastructural analysis of cartilage
Ribs from 7-day-old mice were dissected and fixed overnight in 4% PFA/2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer followed by three washes in 0.1 M sodium cacodylate buffer. Samples were then incubated in a secondary fix of 3% potassium ferrocyanide buffer with 2% osmium oxide for 2 h. They were washed in distilled water and incubated overnight for 2 h in 0.5% uranyl acetate at 40°C. The samples were washed in distilled water and dehydrated in increasing concentrations of acetone: 50%, 70%, 90% and 100% acetone for 30 min. The acetone was replaced with two changes of propylene oxide, which in turn was replaced with Spurr’s resin. After several changes, the resin was polymerised by incubating at 60°C for 48 h. Seventy-nanometer sections were cut and stained with 0.3% (w/v) lead citrate, and images were taken on a FEI Tecnai 12 Biotwin electron microscope, recorded on 4489 film (Kodak) and scanned using an Imacon Flextight 848 scanner (Precision Camera & Video).
2.5 Phenotypic analysis of the skeleton
Mice at 63 days of age were sacrificed, and bone length measurements were made from whole-body radiographs. At least 20 mice were measured for both treated and control groups, and nested ANOVA was used to assess statistical significance between these two groups. A value of p < 0.05 was considered statistically significant.
2.6 Microarray hybridisation
RNA quality was checked using the RNA 6000 Nano Assay and analysed on an Agilent 2100 Bioanalyser (Agilent Technologies). RNA concentration was quantified using a Nanodrop ultra-low-volume spectrophotometer (Nanodrop Technologies). The hybridisation cocktail was hybridised to Mouse 430_2 oligonucleotide arrays (Affymetrix) according to the manufacturers’ instructions. Arrays were read using an Agilent GeneArray scanner 3000 7G and processed using Affymetrix GCOS (V1.4) software. Statistical analysis was performed using PUMA an R/Bioconductor package for Propagating Uncertainty in Microarray Analysis (http://www.bioinf.manchester.ac.uk/resources/puma/index.html). PPLR is an R package that detects differential gene expression by including probe-level measurement error and calculating the probability of positive log-ratio (PPLR). A PPLR value of 1 indicates significant upregulation whilst PPLR values closer to 0.5 are not significant.
2.7 Blood collection and analysis of SPB
Whole blood was extracted from mice and pooled into 15-ml fractions, and plasma was isolated by centrifugation. Proteins were precipitated as described elsewhere (Carducci et al. 2001), and the samples were subjected to reverse-phase high-performance liquid chromatography (HPLC) on a reverse-phase C18 synergi 4U hydro 80A column (Phenomenex) as per manufacturer’s instructions. Prior to analysis, 4-sodium phenylbutyrate (SPB; special diet services, SCANBUR) and control compounds (phenylacetate and phenylacetylglutamine) were checked for purity by liquid chromatography time of flight mass spectrometry. Control samples were diluted in a range of 10–20 pmol/l for the generation of standard curves.
2.8 Cell culture and transfection
Chinese hamster ovary-B2 (CHO) cells were cultured in Ham’s F-12 media supplemented with 10% FBS, 2 mM l-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin. Human wt matrilin-3 A-domain and the Ile192Asn mutation had previously been sub-cloned into pSecTag2A in-frame to a C-terminal c-myc epitope tag and transfected into CHO cells (Cotterill et al. 2005).
2.9 SPB treatment of CHO cell cultures
Transfected CHO cells were seeded into 75-cm2 vented flasks at a density of ∼1.5 × 106 cells per flask. CHO cells were cultured in SPB (Biomol International, Exeter, UK) administered directly into the culture media at final concentrations of 0 mM (untreated), 0.1, 0.5, 1, 5 and 10 mM. Cells were treated with SPB until confluent at which time protein samples were prepared for SDS-PAGE.
2.10 Sample preparation for SDS-PAGE and Western blotting
Conditioned media was removed, and the cells were lysed for SDS-PAGE and Western blot analysis. To ensure that equal quantities of protein were analysed, untreated and SPB-treated cells were counted using a haemocytometer and equal numbers of cells were resuspended in 1 ml of culture media as appropriate. Media and lysate protein samples were analysed by SDS-PAGE and Western blotting as described previously (Cotterill et al. 2005).
In order to obtain sufficient quantities of cartilage for qRT-PCR and Western blotting studies, we decided to use rib and xiphoid cartilage, which are amenable to accurate and reproducible dissection. Therefore, in the first instance, we demonstrated that rib and xiphoid cartilage had a tissue pathology that was comparable to the tibia growth plate.
3.1 The cartilage growth plate in ribs and xiphoid is disorganised in mice harbouring the Matn3 mutation
3.2 Mutant matrilin-3 is retained within the chondrocytes of both rib and xiphoid cartilage
IHC staining of wild-type (wt) xiphoid and rib cartilage with an anti-matrilin-3 antibody confirmed that matrilin-3 was found exclusively within the ECM of the growth plate as expected (Fig. 1c, d). In contrast, IHC analysis of cartilage from mice homozygous for the mutation demonstrated that the majority of matrilin-3 was retained within the chondrocytes and that there was only minimal staining in the ECM. This retention, which was observed in chondrocytes from all regions of the growth plate, is evident by 5 days of age and still present at 21 days of age. These findings were again consistent with the tibia growth plate as described previously (Leighton et al. 2007).
3.3 Ultrastructural analysis of cartilage showed enlarged individual cisternae of rER within rib chondrocytes from mutant mice
In the wild-type growth plate, the proliferative cells were flatter than resting chondrocytes and formed well-organised and tightly stacked two-, four- and eight-cell chondrons. However, in cartilage from mutant mice, the proliferative cells were generally slightly enlarged due to their dilated cisternae, which affected the spatial organisation of individual cells within the chondrons since they were unable to align as closely (data not shown).
The hypertrophic chondrocytes in the wild-type growth plates were generally rectangular in shape, and the condensed chromatin was clearly visible. However, in mutant mice, the hypertrophic cells were more irregular in shape, and there were clear remnants of intracellular protein (Fig. 2).
Overall, these pathological findings were consistent with those seen in the tibia growth plate as described previously (Leighton et al. 2007) and validated the use of rib and xiphoid cartilage for gene and protein expression studies. However, in characterising these tissues, we noted that after approximately 7 days of age the central part of the ribs began to ossify, which significantly reduced the number of chondrocytes that could be isolated. We therefore decided to use rib cartilage for the 5-day study and xiphoid cartilage for the 21-day study.
3.4 Gene expression profiling shows a significant activation of the UPR in mutant chondrocytes at 5 days of age that is still maintained at 21 days of age
A microarray hybridisation was performed on RNA isolated from the chondrocytes of 5-day-old rib cartilage from wild-type and mutant mice
Gene and/or protein name
NCBI mouse gene ID
Fold change (mut vs. wt)
Cysteine-rich with EGF-like domains 2
Heat shock protein 90 kDa beta (Grp94), member 1
Transformation-related protein 53 binding protein 1
Arginine-rich, mutated in early stage tumours
Protein disulfide isomerase-associated 6
Protein disulfide isomerase-associated 4 (Erp72)
DnaJ (Hsp40) homologue, subfamily A, member 4
Solute carrier family 35, member B1
Serine (or cysteine) peptidase inhibitor, clade A, member 3 N
Mannoside acetylglucosaminyltransferase 2
DnaJ (Hsp40) homolog, subfamily C, member 3
Signal peptidase complex subunit 3 homolog (S. cerevisiae)
Heat shock 70 kDa protein 5 (glucose-regulated protein BiP)
Signal peptidase complex subunit 2 homolog (S. cerevisiae)
DnaJ (Hsp40) homologue, subfamily B, member 1
Protein disulfide isomerase-associated 3 (Erp 57)
Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1
In order to characterise further the UPR in mutant chondrocytes at 5 days of age, we also examined the downstream mediators of the ER stress response, which included the cleavage of the ER membrane-anchored transcription factor ATF6 and the activation by splicing of transcription factor X-bp1. Both of these factors have been shown to be activated in a mouse model of PSACH-MED caused by a Comp mutation (Pirog-Garcia et al. 2007) and the former in a mouse model of MCDS caused by a mutation in col10a1 (Rajpar et al. 2009). We saw no evidence of the cleavage of ATF6 in either the wild-type or mutant chondrocyte protein extractions, compared to a positive control from the MCDS mouse (Supplemental Fig. S1). Furthermore, there were no differences between the splicing of X-bp1 mRNA in either wild-type or mutant chondrocytes.
3.5 ER stress does not lead to increased chondrocyte apoptosis in rib cartilage at 5 days of age
3.6 The effect of treating mutant mice with sodium phenylbutyrate as an aid to alleviate the phenotype
Mutant mice were fed standard mouse chow pellets supplemented with SPB at a concentration of 7 g/kg diet (effective daily consumption ∼1 g SPB/kg body weight) in an attempt to aid the folding and secretion of mutant matrilin-3 and alleviate the ER stress/UPR. Untreated mice were fed with food without SPB. Quantification of blood plasma showed the presence of SPB at a concentration of 100 μmol/l. Furthermore, SPB was detected in the stomachs of mice whose diet consisted of milk from their mothers who themselves were on the SPB diet (data not shown).
Microarray hybridisations were performed on RNA isolated from rib chondrocytes of 5-day-old treated and untreated mutant mice
Expression fold change (treated vs untreated)
Significance value (PPLR)
Expression levels (microarray)
Erp 57 (Pdia3)
Finally, to determine whether treatment with SPB aids the secretion of mutant protein into the ECM, we used IHC staining on fixed sections from 3-week-old tibia growth plates. However, there was no apparent improvement in the secretion of mutant matrilin-3 in SPB-treated mice since matrilin-3 staining was indistinguishable in tibia growth plates from treated and untreated mutant mice (Fig. 7e).
We wished to determine if SPB could aid in the secretion of mutant protein from a cell culture model of mutant matrilin-3 A-domains that we have previously characterised (Cotterill et al. 2005; Fresquet et al. 2008). Increasing concentrations of SPB (0.1 to 10 mM) failed to aid the secretion of the mutant matrilin-3 A-domain (Supplemental Fig. S3); however, we did notice that the addition of SPB up to a final concentration of 5 mM increased the expression of both wild-type and mutant proteins. The addition of 10 mM SPB reduced the yields of recombinant protein, although they were still higher than without the addition of SPB (Supplemental Fig. S3) and also had a detrimental effect on cell viability regardless of whether the cells were expressing mutant or wild type matrilin-3 A-domains (not shown).
The aim of this study was to characterise the initial cellular response to the expression of mutant matrilin-3 with the intention of identifying the key genetic pathway(s) that are ultimately responsible for decreased chondrocyte proliferation and dysregulated apoptosis at 3 weeks of age (Leighton et al. 2007). Our data from this current study demonstrate that a UPR is rapidly activated in the post-natal period, which is most likely due to accumulation of misfolded matrilin-3 within the rER of growth plate chondrocytes.
We initially demonstrated that rib and xiphoid cartilage from mutant animals displayed a tissue pathology that was similar to that previously reported for the growth plates of the major long bones (i.e. femur and tibia; Leighton et al. 2007). This disease pathology is characterised by the intracellular retention of mutant matrilin-3 from birth and a generalised growth plate dysplasia characterised by abnormal chondrocyte morphology and their misalignment within the proliferative zone. This observation suggests that weight bearing is not a factor in the expression and intracellular retention of mutant matrilin-3, which is consistent with similar findings in a pseudoachondroplastic Scottish deerhound (Stevens 1999). Our findings therefore confirm that MED is a generalised cartilage disorder (chondrodysplasia), which manifests itself most profoundly in the growth of the long bones.
The UPR that is activated in mutant chondrocytes in vivo is characterised by the upregulation of key chaperones that are known to be associated with ER stress responses or protein folding and quality control. These include BiP (which is a member of the Hsp70 family), Grp94, members of the Hsp40 protein family (Dnajb1, Dnajc3 and Dnaja4) and also Pdia3 (ERp57), Pdia4 (ERp72) and Pdia6. The PDI family of protein disulphide isomerase-associated proteins (PDIA2-6) are ER resident proteins that catalyse in turn the formation, reduction and isomerisation of disulphide-bonded proteins such as matrilin-3 (Hatahet and Ruddock 2007). PDI can also interact with the lectin chaperones calreticulin and calnexin, which were also increased in mutant chondrocytes. Calnexin and calreticulin bind to and mediate the folding of newly synthesised glycoproteins and are important in monitoring the N-linked glycans that persist on unfolded or misfolded glycoproteins. The increased expression of these two genes in mutant chondrocytes might be expected since matrilin-3 has a potential N-linked glycosylation site (Wagener et al. 1997). The upregulation of Mgat2 is further evidence that mutant matrilin-3 is being recognised and processed by the Canx/Calr folding pathway. Mgat2 encodes a Golgi enzyme called monoacylglycerol acyltransferase 2, which catalyses an essential step in the conversion of oligomannose to complex N-glycans, and mice deficient in Mgat2 have a congenital disorder of glycosylation type IIa (Wang et al. 2002). Furthermore, patients with the autosomal recessive disease carbohydrate-deficient glycoprotein syndrome type II have been shown to have mutations in MGAT2 (Tan et al. 1996).
We have previously shown in a cell culture model (Cotterill et al. 2005) that mutant matrilin-3 A-domains are predominantly unfolded in the rER of cells and are directly associated with ERp72 (Pdia4), a member of the protein disulphide isomerase family. This is consistent with the ∼3-fold increase in the expression of Pdia4 in mutant mouse chondrocytes (Table 1). Interestingly, in the cell culture system, no direct association was seen with PDI, BiP or Grp94, and this disparity in the chaperone protein profile between the in vitro and in vivo studies is most likely due to differences in the recognition and processing of full-length mutant matrilin-3 (this study) compared to the mutant A-domain alone (Cotterill et al. 2005). For example, the potential N-linked glycosylation site of matrilin-3 is in the second EGF-like domain between residues (Asn321–Gly322–Ser323) and not the A-domain (Wagener et al. 1997).
In addition to chaperone/heat shock proteins and members of the lectin/PDI folding complexes, we also identified genes by the microarray studies that are known to play a role in ER-associated degradation such as homocysteine-inducible, endoplasmic-reticulum-stress-inducible, ubiquitin-like domain member 1 (Herpud1; Kim et al. 2008), suggesting that some misfolded matrilin-3 might be targeted for degradation.
Finally, amongst the genes whose expression was upregulated in mutant chondrocytes were several genes that have only recently been implicated in ER stress. For example, cysteine-rich with EGF-like domains 2 (Creld2), which was the most highly upregulated gene in mutant chondrocytes has recently been reported as a novel ER-stress-inducible gene (Oh-hashi et al. 2009). The promoter region of Creld2 contains a typical ER-stress-responsible element (ERSE) and, whilst it is believed to be involved in the folding and transport of proteins through the ER and Golgi, its precise role has yet to be determined (Ortiz et al. 2005). Another gene over-expressed to a similar extent as Creld2 was arginine-rich, mutated in early stage of tumours (Armet; also known as MANF), which is known to be activated by the UPR via an ERSE-II element (Mizobuchi et al. 2007). Furthermore, over-expression of Armet in cell culture has been shown to inhibit cell proliferation and ER-stress-induced apoptosis (Apostolou et al. 2008), both of which are key features of the growth plate dysplasia in the MED-Matn3 mouse model (Leighton et al. 2007).
We were able to determine that the post-natal activation of a UPR in mutant chondrocytes did not result in an immediate increase and/or dysregulation of CHOP-mediated apoptosis by 5 days of age. Furthermore, our data suggest that at 5 days of age the UPR is still primarily BiP-mediated and has not progressed to other downstream mediators, such as the IRE1 and PERK receptors as shown by a lack of ATF6 cleavage or X-bp1 splicing. Unfortunately, due to technical constraints, it was not possible to examine chondrocyte proliferation at this age since the mice are too small for peritoneal injection. In the long term, however, determining the precise time of onset of reduced chondrocyte proliferation and spatially dysregulated apoptosis in vivo will be important for understanding the disease process and delineating the influence of these two pathological components of MED.
We hypothesised that alleviating the rER stress and/or UPR in mutant chondrocytes may have an impact on cell phenotype and might lessen or even prevent the reduction in cell proliferation and increase spatially dysregulated apoptosis, eventually restoring normal long-bone growth. SPB is a butyrate analogue that is approved for clinical use as an ammonia scavenger in subjects with urea cycle disorders. It is also a known transcriptional regulator that may act by inhibiting histone deacetylase (Candido et al. 1978). Previous studies have shown that SPB has properties that aid the trafficking and secretion of mutant proteins in a variety of protein folding diseases such as cystic fibrosis (Rubenstein and Zeitlin 2000), hereditary hemochromatosis (de Almeida et al. 2007) and glaucoma (Tsang et al. 2007) and has been found to prevent aggregation of proteins in vitro in neurodegenerative diseases (Ryu et al. 2005). Finally, oral dosage of SPB improved the phenotype in a mouse model of type 2 diabetes (Ozcan et al. 2006) that was linked to ER cell stress (Ozcan et al. 2004).
We used a similar dosage protocol to that of Ozcan et al. (2006); however, SPB administered at this dosage in the food did not have an effect on MED disease severity as determined by body weight and bone length measurements at 9 weeks of age. Furthermore, there was no significant improvement in chondrocyte proliferation and apoptosis at 3 weeks of age. Although there appeared to be a modest increase (∼8%) in chondrocyte proliferation at 3 weeks of age, this was not statistically significant, which might in part be due to the natural variability between litters. Furthermore, at 5 days of age, microarray analysis showed no changes in the expression levels of chaperones in mutant chondrocytes following treatment with SPB. Nevertheless, by 3 weeks of age, there was a modest but significant decrease in the protein levels of ERp72, BiP and Grp94, but ultimately this did not affect the trafficking of mutant matrilin-3, which remained predominately intracellular regardless of whether the mice were treated with SPB or not. SPB is known to regulate general transcription due to its role as a histone deacetylase inhibitor. The microarray results for [m/m vs. wt] and [treated vs. untreated] had a similar overall proportion of downregulated genes with 47% of genes downregulated in [m/m vs. wt] and 43% of genes downregulated in [treated vs. untreated], suggesting that SPB did not have a major effect on the global transcription of genes in chondrocytes.
In a parallel study, we also investigated the effect of SPB treatment on a mouse model of metaphyseal chondrodysplasia type Schmid (MCDS) that we have recently described (Rajpar et al. 2009). However, like the Matn3-MED mouse, SPB treatment failed to improve the disease phenotype.
One possible reason for the SPB treatment having no effect on mutant matrilin-3 secretion, ER stress, chondrocyte proliferation and apoptosis may be due to the avascular nature of cartilage. There are no blood capillaries within cartilage, and only the perichondrium is vascularised. Instead, chondrocytes get their nutrient supply by diffusion from blood vessels of the perichondrium. Compressive loading of cartilage creates a pumping action due to the gel-like and hydrated nature of cartilage that facilitates this diffusion. Since there is no readily accessible blood supply to the chondrocytes, this will limit the diffusion of SPB into the chondrocytes. Therefore, it is possible that SPB takes time to enter the chondrocytes or may not be reaching them at all. Targeting of SPB directly into cartilage may help to overcome this potential problem. However, we were unable to show that treatment with SPB could aid in the secretion of mutant matrilin-3 A-domains in vitro. Interestingly, treatment with SPB up to 5 mM did increase the overall expression of recombinant protein and may be acting by reducing the ER stress in cells induced to over-express a recombinant protein. This finding is outside the scope of the current study but deserves further investigation.
In summary, MED is caused by a defect in the trafficking and secretion of mutant matrilin-3 that causes ER stress and a UPR in the post-natal period. Treatment with SPB may have an effect on ER stress and UPR at later stages of the disease, but it is too late or has insufficient efficacy to influence the disease phenotype. However, these preliminary studies using chemical chaperones will hopefully pave the way for developing suitable therapies for patients with MED and related diseases.
This work was supported by grants from the Wellcome Trust (MDB is the recipient of a Wellcome Trust Senior Research Fellowship in Basic Biomedical Science; Grants 071161/Z/03/Z and 084353/Z/07/Z), the Arthritis Research Campaign (SN was the recipient of an ARC Ph.D. studentship) and European Commission FP6 (LSHM-CT-2007-037471). The research was undertaken in the Wellcome Trust Centre for Cell-Matrix Research and the Histology, Microarray and Transgenic Core Facilities of the Faculty of Life Sciences at the University of Manchester. Electron microscopy was performed by Roger Meadows.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.